Dyne Therapeutics, Inc. (DYN)

Market Cap	700.91M
Revenue (ttm)	n/a
Net Income (ttm)	-208.13M
Shares Out	61.38M
EPS (ttm)	-3.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	428,385
Open	11.50
Previous Close	11.42
Day's Range	11.18 - 11.61
52-Week Range	6.40 - 15.60
Beta	0.79
Analysts	Strong Buy
Price Target	27.20 (+135.29%)
Earnings Date	Oct 30, 2023

About DYN

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachuset...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2020
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: DYN

Analyst Forecast

According to 5 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price forecast is $27.2, which is an increase of 135.29% from the latest price.

Price Target

$27.2

(135.29% upside)

Analyst Consensus: Strong Buy